NYSE:USNA - USANA Health Sciences Stock Price, Price Target & More

USANA Health Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "USNA."

USANA Health Sciences declared that its Board of Directors has initiated a share buyback plan on Wednesday, July 26th 2017, which permits the company to buyback $64,600,000.00 in shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 46% of its stock through open market purchases. Stock buyback plans are typically an indication that the company's board believes its shares are undervalued.

USANA Health Sciences, Inc. (NYSE:USNA) posted its quarterly earnings data on Tuesday, April, 24th. The company reported $1.19 EPS for the quarter, beating the Zacks' consensus estimate of $1.05 by $0.14. The business earned $292 million during the quarter, compared to the consensus estimate of $268.93 million. USANA Health Sciences had a return on equity of 27.92% and a net margin of 6.47%. The company's revenue for the quarter was up 14.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.91 earnings per share. View USANA Health Sciences' Earnings History.

USANA Health Sciences is scheduled to release their next quarterly earnings announcement on Monday, July, 23rd 2018. View Earnings Estimates for USANA Health Sciences.

USANA Health Sciences issued an update on its FY18 earnings guidance on Tuesday, April, 24th. The company provided earnings per share guidance of $4.25-4.55 for the period, compared to the Thomson Reuters consensus estimate of $4.37. The company issued revenue guidance of $1.13-1.17 billion, compared to the consensus revenue estimate of $1.12 billion.

2 equities research analysts have issued 1 year target prices for USANA Health Sciences' shares. Their predictions range from $95.00 to $95.00. On average, they expect USANA Health Sciences' share price to reach $95.00 in the next year. View Analyst Ratings for USANA Health Sciences.

Some companies that are related to USANA Health Sciences include Stada Arzneimittel (STDAF), Foamix Pharmaceuticals (FOMX), Chromadex (CDXC), Mediwound (MDWD), Natural Alternatives International (NAII), Pharmacyte Biotech (PMCB), Mannatech (MTEX), China Jo-Jo Drugstores (CJJD), Cyanotech (CYAN), GLG Life Tech (GLGLF), ImmuDyne (IMMD), FitLife Brands (FTLF), Nutra Pharma (NPHC), Tauriga Sciences (TAUG) and True Drinks Holdings, Inc Common Stock (TRUU).

News coverage about USNA stock has trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. USANA Health Sciences earned a news impact score of 0.03 on Accern's scale. They also gave headlines about the company an impact score of 45.27 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

USANA Health Sciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include WENTZ MYRON W (43.80%), BlackRock Inc. (3.45%), Dimensional Fund Advisors LP (3.23%), Schroder Investment Management Group (1.38%), Matarin Capital Management LLC (0.65%) and Hood River Capital Management LLC (0.63%). Company insiders that own USANA Health Sciences stock include Daniel A Macuga, David Mulham Mulham, Deborah Woo, G Doug Iiekking, Gilbert A Fuller, Global Ltd Gull, James Bramble, Jim Brown, Kevin Guest, Myron W Wentz, Paul A Jones, Robert Auciaux and Walter Noot. View Institutional Ownership Trends for USANA Health Sciences.

USNA stock was sold by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, BNP Paribas Arbitrage SA, UBS Group AG, Hays Advisory LLC, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp, Guggenheim Capital LLC, Camarda Financial Advisors LLC and New York State Common Retirement Fund. Company insiders that have sold USANA Health Sciences company stock in the last year include Daniel A Macuga, David Mulham Mulham, G Doug Iiekking, Gilbert A Fuller, Global Ltd Gull, James Bramble, Jim Brown, Kevin Guest, Myron W Wentz, Paul A Jones and Walter Noot. View Insider Buying and Selling for USANA Health Sciences.

USNA stock was bought by a variety of institutional investors in the last quarter, including Matarin Capital Management LLC, Hood River Capital Management LLC, BlackRock Inc., Russell Investments Group Ltd., Millennium Management LLC, Fort L.P., Schwab Charles Investment Management Inc. and Mackay Shields LLC. View Insider Buying and Selling for USANA Health Sciences.

Shares of USNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of USNA stock can currently be purchased for approximately $115.45.

USANA Health Sciences has a market capitalization of $2.80 billion and generates $1.05 billion in revenue each year. The company earns $62.53 million in net income (profit) each year or $4.06 on an earnings per share basis. USANA Health Sciences employs 1,810 workers across the globe.

USANA Health Sciences' mailing address is 3838 West Parkway Blvd, Salt Lake City UT, 84120. The company can be reached via phone at 801-954-7100 or via email at [email protected]